EpiPen settlement paying out more than $1,000 to some class members

Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.

EpiPen settlement overview:

• Who: EpiPen purchasers are receiving checks worth thousands of dollars from a $609 million settlement.

• Why: Pfizer, Meridian Medical Technologies, King Pharmaceuticals and Mylan agreed to pay a combined $609 million to resolve claims that they conspired to extend their monopoly on expensive EpiPen prescriptions.

• Where: Nationwide.

Top Class Actions readers from around the country have begun to receive checks and digital payments from a $609 million EpiPen class action lawsuit settlement — and some report receiving more than $1,000.

The settlement benefits individuals and entities who paid for or provided reimbursement for branded or generic EpiPens for themselves, their families, insureds, plan participants, employees or beneficiaries between Aug. 24, 2011, and Nov. 1, 2020. 

The EpiPen settlement does not benefit government entities, single flat co-pay consumers, direct purchasers, fully insured health plans, those who excluded themselves from the settlement and certain others.

Plaintiffs in the EpiPen class action lawsuit claimed Pfizer, Meridian Medical Technologies, King Pharmaceuticals and Mylan conspired to prolong their monopoly on EpiPen prescriptions. These companies allegedly issued large rebates to insurers and Medicaid plans if those plans refused to cover less expensive competitor medications. This scheme allegedly allowed the businesses to sell EpiPens at exorbitant prices which increased from $100 to $600 in less than 10 years. 

The defendants did not admit any wrongdoing but agreed to resolve the EpiPen class action lawsuit with $609 million in settlement payments. Pfizer, Meridian and King agreed to pay $345 million, while Mylan agreed to pay an additional $264 million.

Under the terms of the settlement, class members could receive a cash payment based on the amount they paid for EpiPen products. Eighty percent of the settlement funds were allocated to third-party payor compensation. The remaining 20 percent of the settlement funds were allocated to individual patients and consumers.

Top Class Actions readers report receiving significant payments from the EpiPen class action lawsuit settlement. One reader reportedly received a payment of over $3,700, while others received hundreds in checks and digital payments.

Have you gotten a payment from the EpiPen settlement? Let us know in the comments below!

Claimants in the class action lawsuit settlement are represented by Elizabeth C Pritzker of Pritzker Levine LLP, Warren T. Burns of Burns Charest LLP, Paul J. Geller of Robbins Geller Rudman & Dowd LLP, Lynn Lincoln Sarko of Keller Rohrback LLP and Rex A. Sharp of Sharp Law LLP.

The EpiPen class action multidistrict litigation is In re: EpiPen Marketing, Sales Practices, and Antitrust Litigation, Civil Action No. 2:17-md-02785-DDC-TJJ (MDL No: 2785), in the U.S. District Court for the District of Kansas.

Read About More Class Action Lawsuits & Class Action Settlements:

• Settlement checks in the mail from Coppertone, Takata, Experian, others
• DirecTV, Celsius, other class action settlement checks in the mail
• Enfamil, Facebook, other settlement checks in the mail
• StubHub, Apple, other class action settlement checks in the mail